[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bin Cao\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":108},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,62,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100609375","phase-4-short-term-antibiotic-therapy-in-mycobacterium-avium-complex-pulmonary-disease-100609375",false,"NCT07213765","Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease","Inclusion Criteria:\n\n1. Patients voluntarily participate in this study and sign the Informed Consent Form.\n2. Age ≥ 18 years and ≤75 years; gender unrestricted.\n3. Confirmed diagnosis of MAC pulmonary disease per ATS\u002FIDSA 2020 guidelines or Chinese Guidelines for Diagnosis and Treatment of Nontuberculous Mycobacterial Diseases (2020 edition), with imaging features consistent with nodular bronchiectatic type.\n4. No prior anti-MAC treatment within the 3 months preceding screening.\n5. For premenopausal women of childbearing potential who are not surgically sterile:\n\n   Must use a medically accepted contraceptive method (e.g., intrauterine device, hormonal contraception, or condom) during the study period and for 3 months following the last dose of investigational treatment.\n\n   Serum or urine human chorionic gonadotropin (hCG) test must be negative within 72 hours prior to enrollment.\n\n   Must not be breastfeeding. Male patients with partners of childbearing potential must use effective contraception during the study period and for 3 months after the last dose.\n6. Organ function criteria met within one week prior to enrollment:\n\ni. Hemoglobin ≥60 g\u002FL; ii. Neutrophil count ≥0.5 × 10⁹\u002FL; iii. Platelet count ≥60 × 10⁹\u002FL; iv. Serum total bilirubin ≤3 × upper limit of normal (ULN); v. Aspartate aminotransferase (AST) ≤3 × ULN; vi. Alanine aminotransferase (ALT) ≤3 × ULN; vii. Serum creatinine \\\u003C2 × ULN OR creatinine clearance ≥60 mL\u002Fmin; viii. Blood urea nitrogen (BUN) ≤200 mg\u002FL; ix. Urinalysis: Proteinuria \\\u003C++; if proteinuria is +, 24-hour total protein must be \\\u003C500 mg.\n\nx. Fasting blood glucose within normal range OR stable glycemic control in diabetic patients.\n\nxi. Cardiac function: No myocardial infarction in the preceding 6 months; No unstable angina or severe arrhythmias; New York Heart Association (NYHA) functional class \\>II.\n\nExclusion Criteria:\n\n1. History of allergy to any study drug in the treatment regimen.\n2. Mixed infections with multiple mycobacteria, bacteria, fungi, or viruses (e.g., HIV coinfection).\n3. Presence of congenital\u002Facquired immunodeficiency disorders, active pulmonary malignancy (primary or metastatic), or other malignancies requiring chemotherapy\u002Fradiation therapy during the screening or study period.\n4. History of solid organ transplantation.\n5. Currently undergoing dialysis.\n6. Uncontrolled radiation pneumonitis requiring steroid or immunoglobulin pulse therapy, active interstitial lung disease with clinical evidence, uncontrolled and significant pleural effusion or pericardial effusion.\n7. Unstable systemic comorbidities including:\n\n   Hypertensive crisis; Unstable angina; Congestive heart failure (NYHA Class III\u002FIV); Myocardial infarction within the preceding 6 months; Severe psychiatric disorders requiring medication (e.g., schizophrenia, bipolar disorder); Severe hepatic or renal dysfunction (e.g., Child-Pugh Class C cirrhosis, eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²); Neurodegenerative diseases (e.g., Alzheimer's disease).\n8. Poor gastrointestinal function or malabsorption syndrome.\n9. Receipt of other investigational drugs within 4 weeks prior to the first study drug administration.\n10. Concurrent participation in another interventional clinical trial, unless it is an observational\u002Fnoninterventional study OR follow-up phase of a completed intervention trial.\n11. Any physical examination findings or clinical tests deemed by the investigator as likely to:\n\nInterfere with study results; Increase risks of complications during treatment.","ALL","18 Years","75 Years",{"count":19,"type":20},188,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The goal of this clinical trial is to learn if adding contezolid works to shorten the length of treatment in mycobacterium avium pulmonary disease in adults. It will also learn about the safety of extended usage of contezolid. The main questions it aims to answer are:\n\nDoes adding contezolid to standard regimen decrease the bacterial load, lesion severity and improve the life quality of patients with mycobacterium avium pulmonary disease? What medical problems do participants have when taking contezolid for an extended length? Researchers will compare standard regimen plus contezolid to standard regimen alone to see if contezolid helps further decrease the bacterial load, lesion severity and improve the life quality of patients with mycobacterium avium pulmonary disease?\n\nParticipants will:\n\nTake contezolid and standard regimen (azithromycin, ethambutol, and rifampicin) for 6 months, contezolid is administered every day while other drugs are taken three times a week OR take standard regimen three times a week for 12 months.\n\nVisit the clinic once every 1 month for checkups and tests.",[26],"Mycobacterium Avium Complex Pulmonary Disease",[26,28,29],"non-tuberculous mycobacterium","contezolid","RECRUITING","2025-10-02",{"date":33,"type":34},"2025-10-09","ACTUAL",{"date":36,"type":34},"2025-07-24",{"date":38,"type":20},"2028-12-31",{"name":40,"class":41},"Bin Cao","OTHER",6,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},"100599431","phase-4-short-term-bactericidal-effect-of-contezolid-in-mac-pd-100599431","NCT07084402","Short-term Bactericidal Effect of Contezolid in MAC-PD","Short-term Bactericidal Effect of Contezolid in Mycobacterium Avium Complex Pulmonary Disease","CONTE-MAC",{"count":19,"type":20},[23],"The goal of this clinical trial is to learn if contezolid works to treat mycobacterium avium complex pulmonary disease in adults. It will also learn about the safety of contezolid. The main questions it aims to answer are:\n\nDoes adding contezolid to standard regimen further decrease the bacterial load in patients' sputum compared with current standard regimen? What medical problems do participants have when taking contezolid along with standard regimen? Researchers will compare standard regimen plus contezolid to standard regimen alone to see if contezolid helps further lower the count of bacteria in patients' sputum.\n\nParticipants will:\n\nTake contezolid and standard regimen (azithromycin, ethambutol and rifampicin) or standard regimen only for 6 months, contezolid is administered every day while other drugs are taken 3 times a week Visit the clinic once every 1 month for checkups and tests.",[26],"2025-09-13",{"date":56,"type":34},"2025-09-18",{"date":36,"type":34},{"date":59,"type":20},"2027-12-31",{"name":40,"class":41},3,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":68,"targetDuration":4,"studyType":21,"phases":70,"briefSummary":71,"conditions":72,"keywords":73,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":81,"leadSponsor":82,"locationsCount":42},"100606324","phase-4-prevention-of-recurrence-with-cordyceps-sinensis-in-mycobacterium-avium-complex-pulmonary-disease-100606324","NCT07174076","Prevention of Recurrence With Cordyceps Sinensis in Mycobacterium Avium Complex Pulmonary Disease","Inclusion Criteria:\n\n1. Patients voluntarily participate in the study and sign the informed consent form.\n2. Age between 18 and 75 years, inclusive; gender unrestricted.\n3. Confirmed diagnosis of MAC (Mycobacterium avium complex) lung disease according to either the 2020 ATS\u002FIDSA guidelines or the Chinese Guideline for Diagnosis and Treatment of Nontuberculous Mycobacterial Disease (2020 edition). Imaging findings at baseline must show a nodular bronchiectatic pattern prior to treatment initiation.\n4. Completed the recommended treatment regimen for nodular-bronchiectatic MAC lung disease (macrolide + ethambutol + rifampin, with minimum 12-month duration) per the above guidelines within 3 months prior to screening; Fully completed the anti-infective treatment phase of this study. Participants must achieve bacteriologic negativity (two consecutive negative sputum cultures with an interval ≥4 weeks) by the end of their treatment course.\n5. For non-surgically sterilized women of childbearing potential:\n\n   Must use a medically approved contraceptive method (e.g., intrauterine device, hormonal contraceptives, or condoms) during the study period and for 3 months post-last treatment dose. A negative serum\u002Furine pregnancy test must be confirmed within 72 hours prior to enrollment.\n\n   Must not be lactating at screening.\n\n   For male participants with partners of childbearing potential:\n\n   Must use effective contraception during the study and for 3 months post-last treatment dose.\n6. Organ Function Requirements (Met Within 1 Week Prior to Enrollment):\n\ni. Hemoglobin ≥60 g\u002FL; ii. Neutrophil count ≥0.5 × 10⁹\u002FL; iii. Platelet count ≥60 × 10⁹\u002FL; iv. Serum total bilirubin ≤3× upper limit of normal (ULN); v. Aspartate aminotransferase (AST) ≤3× ULN; vi. Alanine aminotransferase (ALT) ≤3× ULN; vii. Serum creatinine \\\u003C2× ULN or creatinine clearance ≥60 mL\u002Fmin; viii. Blood urea nitrogen (BUN) ≤200 mg\u002FL; ix. Urine protein \\\u003C++ on dipstick; if trace (+), 24-hour urine protein must be \\\u003C500 mg; x. Fasting glucose within normal range \\*\\*or\\*\\* controlled stable glycemic levels in diabetic patients; xi. Cardiac function: No myocardial infarction in the past 6 months, no unstable angina, no severe arrhythmias, and New York Heart Association (NYHA) functional class ≤II.\n\nExclusion Criteria:\n\n1. Any allergy to drugs included in the treatment regimen.\n2. Completed anti-MAC therapy for more than 3 months.\n3. Active respiratory tract infection.\n4. Presence of congenital\u002Facquired immunodeficiency diseases, active pulmonary malignancies (primary or metastatic), or any malignant tumors requiring chemotherapy\u002Fradiotherapy during screening or the study period.\n5. History of solid organ transplantation.\n6. Currently undergoing dialysis.\n7. Radiographic pneumonia requiring steroid\u002Fimmunoglobulin pulse therapy, clinically evident active interstitial lung disease, uncontrolled massive pleural effusion\u002Fpericardial effusion.\n8. Unstable concomitant systemic diseases (hypertensive crisis, unstable angina, congestive heart failure, myocardial infarction within the past 6 months, severe psychiatric disorders requiring medication, severe hepatic\u002Frenal dysfunction, neurodegenerative diseases such as Alzheimer's disease).\n9. Poor gastrointestinal function or malabsorption syndrome.\n10. Receipt of other investigational drugs (excluding participation of 2025-KY-004-1) within 4 weeks prior to the first administration of study drug.\n11. Participation in another interventional clinical trial simultaneously, except for observational\u002Fnon-interventional trials or follow-up periods of interventional trials.\n12. Any physical examination findings or clinical laboratory results that the investigator believes may interfere with study outcomes or pose increased risks of complications for the patient's management.",{"count":69,"type":20},300,[23],"The goal of this clinical trial is to learn if cordyceps sinesis capsule (Bailiing Capsule) works to prevent the recurrence of microbiologically cured mycobacterium avium complex pulmonary disease in adults. The main questions it aims to answer are:\n\nDoes cordyceps sinesis capsule (Bailiing Capsule) prevents the recurrence of mycobacterium avium complex pulmonary disease in adults? Researchers will compare cordyceps sinesis capsule (Bailiing Capsule) to a placebo (a look-alike substance that contains no drug) to see if cordyceps sinesis capsule helps to prevent the recurrence of mycobacterium avium complex pulmonary disease.\n\nParticipants will:\n\nTake cordyceps sinesis capsule (Bailiing Capsule) or a placebo (a look-alike substance that contains no drug) for 12 months, both are administered every day.\n\nVisit the clinic once every 3 months for checkups and tests. Take online questionnaires every month.",[26],[74,75,76],"mycobacerium avium complex","recurrence","cordyceps sinesis","2025-09-08",{"date":79,"type":34},"2025-09-15",{"date":36,"type":34},{"date":38,"type":20},{"name":40,"class":41},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100574200","phase-4-antifungal-drugs-in-pulmonary-mucormycosis-100574200","NCT06756191","Antifungal Drugs in Pulmonary Mucormycosis","Evaluation on Efficacy and Safety of Liposomal Amphotericin B(AmBisome® ) Combination with Isavuconazole Versus AmBisome® Alone for Treatment of Patients with Pulmonary Mucormycosis","Inclusion Criteria\n\n* Patients aged 18 years or older diagnosed with pulmonary mucormycosis (PM).\n* Individuals with Probable or proved PM, as indicated by clinical and radiological findings.\n\nExclusion Criteria:\n\n* Patients with a history of pulmonary mucormycosis (PM) who have previously been treated with amphotericin B for a duration exceeding 5 days.\n* Patients who have documented allergies to azoles or amphotericin B regimens\n* Patients with serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, or bilirubin levels exceeding five times the upper limit of normal (ULN).\n* Patients with irreversible heart or liver failure, or those experiencing massive, fatal hemoptysis.\n* Patients who have experienced a myocardial infarction or cerebral infarction.\n* Patients currently receiving extracorporeal membrane oxygenation (ECMO) treatment.\n* Pregnant or breastfeeding individuals. 8.Patients with individual reasons that may prevent them from completing the treatment protocol.",{"count":91,"type":20},312,[23],"Pulmonary mucormycosis (PM) poses a substantial clinical challenge, particularly among immunocompromised patients. The aim of the study is to determine the effectiveness and safety of administering AmBisome at a dose of 5mg\u002Fkg\u002Fday combined with isavuconazole versus using AmBisome for the management of pulmonary mucormycosis",[95],"Pulmonary Mucormycosis",[95,97,98],"Amphotericin B liposome","isavuconazole","NOT_YET_RECRUITING","2024-12-25",{"date":102,"type":34},"2025-01-01",{"date":104,"type":20},"2025-01-10",{"date":106,"type":20},"2026-12-31",{"name":40,"class":41},""]